Traditional techniques for inducing polymerization—or the chemical linking of small molecular units known as monomers to create polymers—inside living tissue have been severely limited by the penetration depth of their activating signals. Previous efforts predominantly relied on infrared (IR) light to trigger this process, but IR light scarcely reaches beyond superficial layers beneath the skin. The Caltech team’s novel approach overcomes this fundamental challenge by harnessing ultrasound, a modality long valued in medical imaging for its noninvasive ability to reach deep tissue depths. The new technique enables precise spatial control, deep inside the body, of where polymers form, all while preserving biocompatibility essential for medical applications.

The foundational concept centers on the use of low-temperature-sensitive liposomes—tiny spherical vesicles comprising protective lipid bilayers—that are well known as carriers in drug delivery systems. By encapsulating crosslinking agents inside these lipid spheres and embedding them in a polymer solution containing the desired monomers, scientists created a composite bioink suitable for direct injection into living tissue. This bioink also contains an imaging contrast agent, specifically gas vesicles derived from bacteria, which serve a dual purpose: they appear clearly in ultrasound imaging and undergo a detectable contrast change upon polymerization, allowing researchers to visualize in real time the spatial and temporal dynamics of the printing process inside the body.

The magic happens when focused ultrasound waves are applied to a defined region, raising the temperature of that microenvironment by a mere 5 degrees Celsius. This seemingly small thermal perturbation is enough to cause the liposomes to release the crosslinking agents, thereby initiating polymerization exclusively in that localized area. The result is an in situ formation of polymer structures—solid, stable networks—directly within targeted tissue, marking a significant advancement beyond surface-level polymer printing or drug delivery. Importantly, this thermo-responsive mechanism ensures that polymer formation is controlled both temporally and spatially, mitigating unintended or off-target effects that often hamper other delivery methodologies.

The researchers named this platform the Deep Tissue In Vivo Sound Printing (DISP) system, an apt descriptor reflecting its ability to “print” inside the living body using sound. The method’s flexibility extends beyond printing simple polymers, enabling the fabrication of complex bioadhesive gels for wound sealing, drug-loaded hydrogels for localized chemotherapy, and even bioelectric hydrogels embedded with conductive nanomaterials such as carbon nanotubes or silver nanoparticles. These electrically conductive hydrogels can potentially interface with biological systems to monitor physiological signals, for example, capturing cardiac activity much like an internal electrocardiogram.

In preclinical experiments with murine models, DISP has demonstrated remarkable efficacy. When hydrogels loaded with doxorubicin—a widely used chemotherapeutic agent—were printed near bladder tumors, researchers observed significantly increased tumor cell death over several days, outperforming traditional methods of drug delivery involving direct injection. This validates not only the precision and localization of the approach but also its capacity to enhance therapeutic outcomes by maintaining high local drug concentrations while minimizing systemic exposure. These encouraging results warrant further investigation into scaling the platform for larger animal models and, eventually, clinical trials in humans.

A key enabler of the DISP platform’s accuracy is the use of bacterial gas vesicles as ultrasound contrast agents. These hollow protein nanostructures dramatically enhance the ability of ultrasound imaging to detect polymerization events in real time. Upon the chemical crosslinking of monomers into a gel network, the gas vesicles undergo structural changes that alter their acoustic properties. This shift is detected as a contrast change in ultrasound images, effectively providing a molecular “signal” that researchers can use to monitor the formation and architecture of printed polymers noninvasively. Such imaging feedback is critical to precisely applying the focused ultrasound, ensuring that printing remains confined to intended regions within dynamic biological environments.

The research team, led by Wei Gao, Professor of Medical Engineering at Caltech, envisions future iterations of the DISP platform augmented by artificial intelligence and machine learning algorithms. These enhancements could enable autonomous, high-precision ultrasound targeting in complex, moving organs such as the beating heart. Integrating automated feedback loops with ultrasound imaging and printing controls could facilitate adaptive, real-time tuning of printing parameters, overcoming challenges posed by intrabody motion and physiological variability. The potential to deploy such “smart” sound printing in living patients promises to accelerate translation of this cutting-edge technology from bench to bedside.

Besides the therapeutic benefits, DISP opens exciting avenues in regenerative medicine and bioelectronics. By printing cells embedded within hydrogels directly at injury sites, the technology could stimulate tissue regeneration with unparalleled spatial accuracy. Meanwhile, printed bioelectronic interfaces crafted in vivo could provide novel means of continuous physiological monitoring or neuromodulation, potentially ushering in new classes of implantable medical devices that self-assemble within the body without invasive surgery.

The multidisciplinary nature of this breakthrough touches upon fields ranging from chemical engineering and materials science to biomedical engineering and medical imaging. The collaborative team included experts from Caltech, the University of Utah, UCLA, USC, and the Terasaki Institute for Biomedical Innovation, demonstrating the power of cross-institutional cooperation in tackling complex biomedical challenges. Supported by several major funding agencies, including the National Institutes of Health and the American Cancer Society, this research represents a significant convergence of innovative materials, imaging contrast agents, and applied physics.

As the next steps, the research team plans to test the DISP system in larger animal models to evaluate the scalability and safety of the method in anatomies more comparable to humans. Moreover, they aim to refine the bioink formulations to optimize biocompatibility, mechanical properties, and functional payload delivery. The integration of AI-driven ultrasound control is anticipated to drastically improve the precision and usability of the platform in clinical settings, holding promise for personalized therapies, minimally invasive surgeries, and localized treatments for a range of diseases.

In summary, the development of the Deep Tissue In Vivo Sound Printing platform is a landmark achievement that redefines the frontiers of in vivo 3D printing and targeted drug delivery. By utilizing focused ultrasound to trigger polymerization within living tissue, the technology overcomes previous depth limitations and opens a new paradigm for printing functional materials directly inside the body. The ability to visualize and control this process in real time adds an unprecedented level of precision, suggesting a future where patients might receive personalized, on-demand treatments with minimal side effects. As this sound-based printing technology matures, it holds transformative potential not just for cancer therapies but also for regenerative medicine, wound healing, and bioelectronic interfaces, promising a new era of medical innovation.

Subject of Research: Deep tissue in vivo 3D printing, ultrasound-triggered polymerization, targeted drug delivery, bioadhesive gels, bioelectric hydrogels.

Article Title: Imaging-guided deep tissue in vivo sound printing

News Publication Date: 8-May-2025

Web References: http://dx.doi.org/10.1126/science.adt0293

Image Credits: Elham Davoodi and Wei Gao

Keywords: Polymers, Drug delivery systems, Targeted drug delivery, Regeneration, Ultrasound

Breast cancer remains a formidable health challenge. Despite advances in medical treatment, statistics remain bleak, with only about one-third of individuals diagnosed with metastatic breast cancer surviving beyond five years. Traditional approaches, including chemotherapy, radiation, and surgical interventions, often lead to significant side effects and the risk of exacerbating the patient’s overall condition. In this landscape of high stakes, Sheybani’s research stands out, as it endeavors to minimize toxicity while enhancing the effectiveness of cancer therapies.

The simplicity of focused ultrasound belies its potential as an innovative tool in cancer treatment. The method harnesses the power of sound waves to create tailored biological responses, effectively “communicating” with the body’s immune system and improving its ability to fight tumors. This communication is particularly crucial given that many standard treatments struggle to penetrate the protective barriers tumors establish to shield themselves from the immune system and pharmacological agents.

Sheybani’s research emphasizes the creation of precise pathways for therapies to navigate tumor barriers, a concept likened to programming the physics of sound waves. By using FUS to disrupt the barrier surrounding a tumor without invasive procedures, the treatments can be made more efficient, allowing for targeted therapy to reach its intended destination unhindered. This approach aims to transform the traditional paradigms of cancer treatment by focusing on individual patient survivorship, yielding significant implications for future therapeutic strategies.

Another facet of Sheybani’s innovative research lies in the concept of guiding therapeutic messages directly to cancer cells. Traditional chemotherapy often indiscriminately affects healthy tissues, raising concerns about collateral damage. Instead, by tuning sound waves to pinpoint specific cancer cells, FUS provides a non-invasive means of delivering treatments directly where they are needed. This precision not only promises fewer harmful side effects but may also enhance the overall effectiveness of cancer treatments.

The ability to signal the immune system to mount a targeted response is a cornerstone of immunotherapeutic strategies and revolutionary in cancer treatment. Focused ultrasound acts as a beacon, alerting the body’s immune defenses to the presence of cancer and potentially enhancing the overall response to immunotherapies. This method of manipulation could fundamentally shift how we perceive the fight against cancer, emphasizing the potential for the immune system to be utilized as a formidable ally in combating malignant growths.

As daunting as breast cancer may seem, Sheybani’s research illuminates multiple promising methodologies for utilizing focused ultrasound in clinical settings. From thermal ablation, which precisely delivers heat to cancer cells until they disintegrate while preserving adjacent healthy tissues, to mechanical ablation, which disrupts stubborn tumors through sonic shocks, the various applications of FUS technology reveal the diverse avenues through which cancer treatment can be enhanced.

The concept of sonodynamic therapy introduces an intriguing layer to her research, wherein specific medications can be activated by precise sonic cues. This not only ensures that drugs are administered only where necessary but also minimizes systemic toxicity, allowing for treatment protocols that could usher in a new era of cancer therapeutics. Additionally, the capability of FUS to temporarily disrupt protective barriers like the blood-brain barrier presents a significant advancement. This technique allows crucial medications easier access to once unreachable cancer sites, positing focused ultrasound as a transformative force in the oncological landscape.

Sheybani’s vision extends beyond the laboratory; her project seeks to improve communication among survivors, caregivers, and clinicians through a collaborative initiative with the UVA Cancer Center. By engaging stakeholders in meaningful discourse, she hopes to align research advancements with patient needs, paving the way for translational breakthroughs in cancer therapy. This initiative amplifies the importance of understanding the patient experience and integrating those insights into the research model.

The magnitude of the U.S. Department of Defense Breast Cancer Research Program’s recognition further emphasizes the promise of Sheybani’s work. Only granted to one researcher nationwide in fiscal year 2024, the Era of Hope Scholar Award underscores the significance of innovative work poised to redefine standards in cancer research and treatment methodologies. Experts in the field, such as Amy Bouton, have expressed their enthusiasm for the groundbreaking nature of Sheybani’s research, recognizing it as a vital leap toward addressing the complexities of breast cancer.

Sheybani herself articulates the urgency behind her research, noting the troubling rise of breast cancer incidence among younger women and the critical need for treatments that are less toxic and invasive. The dual goals of enhancing patient survivorship and reshaping cancer treatment paradigms reflect the broader aspirations of modern oncological research. As she and her team delve deeper into the mechanics of focused ultrasound, the hope is to arrive at practical solutions that can be rapidly translated into clinical applications.

Unquestionably, Natasha Sheybani’s pioneering work at the intersection of engineering and cancer treatment symbolizes a beacon of hope for many grappling with the implications of metastatic breast cancer. Through innovative techniques and a commitment to advancing patient care, her research may indeed reshape the future landscape of oncology, giving rise to treatments that not only combat cancer effectively but also prioritize the well-being of the patient.

The journey ahead is fraught with challenges, yet it is defined by an unwavering commitment to push boundaries and explore the uncharted territories of cancer treatment. Focusing on the precise use of sound waves as a therapeutic agent projects a future where cancer care is synonymous with precision, personalization, and positivity. As the research progresses, the implications of Sheybani’s work resonate far beyond the confines of the laboratory, heralding a new chapter in the battle against one of the most formidable diseases of our time.

Subject of Research: Focused Ultrasound in Metastatic Breast Cancer Treatment
Article Title: Innovative Techniques with Focused Ultrasound Offer New Hope for Metastatic Breast Cancer
News Publication Date: October 2023
Web References: University of Virginia Engineering
References: None provided
Image Credits: Tom Daly, UVA School of Engineering and Applied Science

Keywords: Focused Ultrasound, Breast Cancer, Cancer Research, Biomedical Engineering, Immunotherapy, Precision Medicine, Natasha Diba Sheybani, U.S. Department of Defense, Era of Hope Scholar Award.